Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes

Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (Humalog(®); Ly-Lis). Two randomized, controlled, open-label, parallel-group, phase 3 studies were conducted to compare the efficacy and safety of SAR-Lis and Ly-Lis, both in combination with insulin glargine (Lantus(®))....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes Technol Ther
Hauptverfasser: Home, Philip, Derwahl, Karl-Michael, Ziemen, Monika, Wernicke-Panten, Karin, Pierre, Suzanne, Kirchhein, Yvonne, Garg, Satish K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Mary Ann Liebert, Inc. 2018
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5771536/
https://ncbi.nlm.nih.gov/pubmed/29355435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2017.0373
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge